AYTU Swings to Profit on Warrant Gains, Revenue Dips 16%

TL;DR

**AYTU's net income looks good on paper, but the revenue drop and reliance on warrant gains mean this biopharma is still a speculative play on its EXXUA launch.**

AI Summary

AYTU BioPharma, Inc. reported a net income of $1.965 million for the three months ended September 30, 2025, an increase from $1.474 million in the same period of 2024. Despite this, net revenue decreased to $13.888 million from $16.574 million year-over-year, representing a 16.3% decline. The company's gross profit also fell to $9.186 million from $11.985 million. Operating expenses saw a reduction to $10.690 million from $12.915 million, primarily due to the elimination of research and development costs and restructuring costs. A significant derivative warrant liabilities gain of $3.784 million contributed positively to the net income. AYTU is strategically shifting focus to commercializing EXXUA for Major Depressive Disorder, anticipating a launch in Q2 fiscal 2026, and has divested its Consumer Health business, which was completed on July 31, 2024. The company also increased its cash and cash equivalents to $32.630 million from $30.952 million at June 30, 2025.

Why It Matters

AYTU's strategic pivot away from its Consumer Health business and clinical development programs, coupled with the upcoming EXXUA launch, signals a focused effort to achieve positive operating cash flows. For investors, the 16.3% revenue decline is a concern, but the net income increase driven by non-operating gains highlights the company's financial engineering. Employees may see a more streamlined organization focused on commercialization, while customers could benefit from new CNS treatments like EXXUA. In a competitive biopharma landscape, AYTU's ability to successfully launch and scale EXXUA will be critical for long-term viability and market positioning against larger players.

Risk Assessment

Risk Level: medium — The company reported a 16.3% decrease in net revenue from $16.574 million in Q3 2024 to $13.888 million in Q3 2025, indicating challenges in its core business. While net income increased to $1.965 million, this was significantly bolstered by a $3.784 million derivative warrant liabilities gain, a non-recurring item, rather than improved operational performance.

Analyst Insight

Investors should closely monitor the upcoming Q2 fiscal 2026 launch of EXXUA and its initial sales performance, as this product is positioned as a major growth catalyst. Given the declining revenue from existing products and reliance on non-operating gains, a 'wait and see' approach is prudent until there's clear evidence of sustainable revenue growth from EXXUA.

Financial Highlights

debt To Equity

1.55

revenue

$13.888M

operating Margin

-11.4%

total Assets

$124.988M

total Debt

$26.777M

net Income

$1.965M

eps

N/A

gross Margin

66.1%

cash Position

$32.630M

revenue Growth

-16.3%

Revenue Breakdown

Key Numbers

• $13.888M — Net Revenue (Decreased from $16.574M in Q3 2024, a 16.3% decline.)
• $1.965M — Net Income (Increased from $1.474M in Q3 2024, primarily due to warrant gains.)
• $3.784M — Derivative Warrant Liabilities Gain (Significant non-operating gain contributing to net income.)
• $32.630M — Cash and Cash Equivalents (Increased from $30.952M at June 30, 2025.)
• 10,188,208 — Common Stock Outstanding (As of November 1, 2025.)
• $10.690M — Total Operating Expenses (Decreased from $12.915M in Q3 2024.)

Key Players & Entities

• AYTU BIOPHARMA, INC. (company) — registrant
• Fabre-Kramer Holdings, Inc. (company) — partner for EXXUA commercialization
• EXXUA (product) — novel first-in-class selective serotonin 5HT1a receptor agonist for MDD
• United States Food and Drug Administration (regulator) — approved EXXUA
• Medomie Pharma Ltd (company) — commercializing ADHD products in Israel and Palestinian Authority
• Lupin Pharma Canada Ltd (company) — commercializing ADHD products in Canada
• The Nasdaq Capital Market (regulator) — exchange where AYTU common stock is registered
• United States Securities and Exchange Commission (regulator) — filing reports to SEC

FAQ

Risk Factors

• Derivative Warrant Liabilities Fluctuation [medium — financial]: The company recognized a significant gain of $3.784 million from derivative warrant liabilities in Q3 2025, compared to $2.880 million in Q3 2024. Fluctuations in the fair value of these warrants can materially impact net income and earnings per share.
• EXXUA Launch and Commercialization [high — operational]: The company is heavily reliant on the successful commercialization of EXXUA for Major Depressive Disorder, with a planned launch in Q2 fiscal 2026. Any delays or market reception issues could significantly impact future revenue and profitability.
• Divestiture of Consumer Health Business [medium — operational]: The divestiture of the Consumer Health business, completed on July 31, 2024, contributed to the decline in net revenue. The company must now ensure its remaining operations and new product launches can offset this lost revenue stream.
• Increased Revolving Credit Facility Usage [medium — financial]: The company increased its revolving credit facility balance to $14.873 million from $9.063 million in the quarter. This indicates increased reliance on short-term debt financing, which could pose a risk if not managed effectively.
• Pharmaceutical Product Approval and Market Access [high — regulatory]: The success of EXXUA is contingent on regulatory approvals and successful market access strategies. Delays or failures in these areas could severely impact the company's strategic direction and financial performance.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on a few key products for revenue, making pipeline success and commercialization critical. The market for treatments for Major Depressive Disorder is competitive, with ongoing innovation and demand for effective therapies.

Regulatory Implications

AYTU's future hinges on the successful regulatory approval and market adoption of EXXUA. The company must navigate the FDA's stringent review process and demonstrate the drug's safety and efficacy. Post-approval, ongoing compliance with manufacturing standards and marketing regulations is essential.

What Investors Should Do

1. Monitor EXXUA development and regulatory milestones.
2. Analyze the impact of the Consumer Health divestiture on future revenue streams.
3. Evaluate the sustainability of net income given reliance on warrant gains.
4. Assess the company's cash burn and financing needs.

Key Dates

• 2024-07-31: Completion of Consumer Health Business Divestiture — Marks a strategic shift away from a previous revenue stream, impacting current period revenue figures and future focus.
• 2025-09-30: End of Third Quarter — Reporting period for the 10-Q, showing a decrease in revenue but an increase in net income driven by non-operating gains.
• 2026-01-01: Beginning of Fiscal Year 2026 — The company anticipates launching EXXUA in Q2 of this fiscal year, a critical event for future growth.

Glossary

Derivative Warrant Liabilities

Financial instruments that give the holder the right, but not the obligation, to purchase or sell an asset (like stock) at a specified price before its expiration. Their value fluctuates with market conditions, impacting the company's financial statements. (A significant gain from these liabilities ($3.784M) positively impacted net income, but their volatility presents a risk.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. It represents a negative balance in retained earnings. (AYTU has a substantial accumulated deficit of $331.570 million, indicating a history of net losses.)

Operating Lease Right-of-Use Assets

Assets recognized under accounting standards for leases, representing the right to use an underlying asset for the lease term. (Represents a portion of the company's non-current assets, valued at $1.010 million.)

Intangible Assets, net

Non-physical assets that have value, such as patents, trademarks, and goodwill. 'Net' indicates that accumulated amortization has been deducted. (A significant portion of non-current assets ($41.430 million) are intangible, likely related to acquired intellectual property or product rights.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, AYTU BioPharma experienced a 16.3% decrease in net revenue, falling to $13.888 million from $16.574 million, largely due to the divestiture of its Consumer Health business. Gross profit also declined. However, net income saw a significant increase to $1.965 million from $1.474 million, primarily driven by a larger gain from derivative warrant liabilities and reduced operating expenses, including the elimination of R&D costs. Total assets saw a modest increase, while cash and cash equivalents grew to $32.630 million.

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AYTU The Nasdaq Capital M

Filing Documents

• aytu20250930_10q.htm (10-Q) — 1164KB
• ex_864168.htm (EX-31.1) — 13KB
• ex_864169.htm (EX-31.2) — 13KB
• ex_864170.htm (EX-32.1) — 8KB
• aytu20231231_10qimg001.jpg (GRAPHIC) — 3KB
• 0001437749-25-034825.txt ( ) — 7770KB
• aytu-20250930.xsd (EX-101.SCH) — 84KB
• aytu-20250930_cal.xml (EX-101.CAL) — 62KB
• aytu-20250930_def.xml (EX-101.DEF) — 522KB
• aytu-20250930_lab.xml (EX-101.LAB) — 471KB
• aytu-20250930_pre.xml (EX-101.PRE) — 573KB
• aytu20250930_10q_htm.xml (XML) — 1245KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Unaudited Consolidated Balance Sheets 4 Unaudited Consolidated Statements of Operations 5 Unaudited Consolidated Statements of Stockholders' Equity 6 Unaudited Consolidated Statements of Cash Flows 7 Notes to the Unaudited Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36

- OTHER INFORMATION

PART II - OTHER INFORMATION 37 Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 5. Other Information 37 Item 6. Exhibits 37

SIGNATURES

SIGNATURES 38 2 Table of Contents CAUTIONARY INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This Report on Form 10Q ("Form 10-Q" or "this report") includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this report, including statements regarding our regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," "potential," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. Such forward-looking statements include, without limitation: our anticipated future cash position; the planned expanded commercialization of our products and the potential future commercialization of our product candidates; our anticipated future growth rates; anticipated sales increases; anticipated net revenue increases; amounts of certain future expenses and cost of goods sold; our plans to acquire additional assets or dispose of assets, anticipated increases or decreases to operating expenses, and selling, general, and administrative expenses; and future events under our current and potential future collaborations. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including without limitation the risks described in "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10K for the year ended June 30, 2025 (" 2025 Form 10-K "), and in the reports we file with the United States Securities and Exchange Commi

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS AYTU BIOPHARMA, INC. UNAUDITED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) September 30, June 30, 2025 2025 ASSETS Current assets: Cash and cash equivalents $ 32,630 $ 30,952 Accounts receivable, net 33,225 31,155 Inventories 10,100 11,434 Prepaid expenses and other current assets 5,154 5,638 Total current assets 81,109 79,179 Non-current assets: Property and equipment, net 500 532 Operating lease right-of-use assets 1,010 1,061 Intangible assets, net 41,430 42,201 Other non-current assets 939 1,204 Total non-current assets 43,879 44,998 Total assets $ 124,988 $ 124,177 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 12,342 $ 10,601 Accrued liabilities 36,700 38,164 Revolving credit facility 14,873 9,063 Current portion of debt 1,857 1,857 Other current liabilities 221 3,379 Total current liabilities 65,993 63,064 Non-current liabilities: Debt, net of current portion 10,447 10,895 Derivative warrant liabilities 20,424 26,334 Other non-current liabilities 4,953 4,918 Total non-current liabilities 35,824 42,147 Commitments and contingencies (note 13) Stockholders' equity: Preferred stock, par value $ 0.0001 ; 50,000,000 shares authorized; no shares issued or outstanding — — Common stock, par value $ 0.0001 ; 200,000,000 shares authorized; 9,911,913 and 8,976,913 shares issued and outstanding, respectively 1 1 Additional paid-in capital 354,740 352,500 Accumulated deficit ( 331,570 ) ( 333,535 ) Total stockholders' equity 23,171 18,966 Total liabilities and stockholders' equity $ 124,988 $ 124,177 The accompanying notes to the unaudited consolidated financial statements are an integral part of this statement. 4 Table of Contents AYTU BIOPHARMA, INC. UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) Three Months Ended September 30,

View Full Filing

View this 10-Q filing on SEC EDGAR